DPH.L Regulatory News (DPH)

Monday, 27 November 2023

Dechra® Pharmaceuticals PLC

("Dechra" or "the Company") 

Directorate Changes

Dechra announces that after 12 years' service with Dechra, Tony Griffin will step down as an Executive Director of the Company with immediate effect. In addition, Tony confirmed that he wishes to retire from his role as Managing Director of DVP Europe, this will be effective as at 31 December 2023.

Consequently, as he is not now seeking re-election at the 2023 Annual General Meeting, Resolution 7 contained in the Notice of Meeting, published on 14 November 2023 has been withdrawn.

Ian Page, Chief Executive Officer, Dechra said:

"I would like to take this opportunity to thank Tony for the significant contribution that he has made to the Group during his tenure. Tony joined us following the acquisition of Eurovet in 2013. This was a transformative acquisition, providing critical mass, new markets, a wide range of complementary products and additional expertise to our management team."

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.